## Role of Transjugular Intrahepatic Portosystemic Shunt in the Management of Portal Hypertension

Richard Parker, MBChB, MRCP

#### **KEYWORDS**

- Transjugular intrahepatic portosystemic shunt Portal hypertension Varices
- Ascites

#### **KEY POINTS**

- Transjugular intrahepatic portosystemic shunt (TIPS) is an effective emergency treatment
  of esophageal variceal bleeding in patients who have failed conventional therapy.
- High-risk patients with advanced cirrhosis experience less rebleeding with better survival
  if TIPS is placed early after variceal bleeding (within 5 days of bleeding).
- TIPS prevents rebleeding more effectively than drug or endoscopic therapy after esophageal variceal bleeding.
- TIPS improves symptoms in treatment-refractory ascites or hepatic hydrothorax, but a survival benefit is yet to be conclusively shown.
- Selected cases of Budd-Chiari respond to TIPS.

#### INTRODUCTION: NATURE OF THE PROBLEM

A transjugular intrahepatic portosystemic shunt (TIPS) is a stent placed via the jugular vein to create a shunt from the portal vein to the systemic circulation via an artificial communication through the liver. TIPS is used to treat complications of portal hypertension by reducing portal pressure (Table 1). After the introduction of TIPS in 1988<sup>1</sup> as a treatment of uncontrolled variceal bleeding, the role of TIPS has expanded (Table 2). TIPS prevents rebleeding in high-risk patients, defined by measures of the severity of portal hypertension or cirrhosis. In addition to variceal bleeding, TIPS is recommended for the management of treatment-refractory or treatment-intolerant

Dr Parker is supported by a UK Medical Research Council grant (G1100448). There are no conflicts of interest to declare.

NIHR Centre for Liver Research, University of Birmingham, Birmingham B15 2TT, UK *E-mail address:* richardparker@nhs.net

Clin Liver Dis 18 (2014) 319–334 http://dx.doi.org/10.1016/j.cld.2013.12.004

Table 1 Hepatic venous pressure gradient (HVPG) in health and disease (see text section for explanation)					
	Normal (mm Hg)	Portal Hypertension (mm Hg)	High-risk Portal Hypertension (mm Hg)	Target After Insertion of TIPS (mm Hg)	
HVPG	5	5–10	>12	<12	

ascites and hepatic hydrothorax, and selected cases of Budd-Chiari syndrome. <sup>12,13</sup> Although considered a safe procedure, TIPS has risks, the most common being provocation or exacerbation of hepatic encephalopathy. This article discusses the indications, insertion, and management of TIPS.

Table 2 Indications and outcomes for TIPS in portal hypertension				
Indication	Outcome			
Esophageal Varices				
Prophylaxis of first bleed	Not indicated			
Treatment of acute bleeding after failure of medical and endoscopic therapy	Bleeding controlled in 90% of patients. Early rebleeding rates 6%–15%. 2,3 50% 1-y survival3			
Preemptive TIPS in high-risk patients (HVPG>20 mm Hg, advanced cirrhosis)	1-y mortality 14%–31% vs 39%–65% with variceal band ligation/drugs alone <sup>4–6</sup>			
Secondary prophylaxis	More effective than drug treatment or endoscopy in prevention of rebleeding but no overall survival benefit <sup>7,8</sup>			
Gastric Varices				
Prophylaxis of bleeding	Not indicated			
Treatment of acute bleeding	TIPS as effective as cyanoacrylate glue with regard to rebleeding and survival, greater morbidity with TIPS <sup>9</sup>			
Prevention of rebleeding	More effective in reducing rebleeding from gastric varices than cyanoacrylate glue (11% vs 38%) <sup>10</sup> but no improvement in overall survival			
Portal hypertensive gastropathy	Control of uncontrolled acute bleeding or transfusion dependent chronic bleeding			
Gastric antral vascular ectasia	Not indicated			
Ascites				
Uncomplicated ascites	Not indicated			
Diuretic-intolerant or diuretic-refractory ascites	TIPS significantly reduces need for paracentesis. Survival benefit unclear			
Hepatic hydrothorax	60% of patients with refractory hydrothorax do not require further drainage			
Budd-Chiari	Moderate Budd-Chiari syndrome unresponsive to anticoagulation; 74%–78% transplant-free survival at 5 y <sup>11</sup>			
Pulmonary Complications of Liver Disease				
Hepatopulmonary syndrome	Not routinely indicated			
Portopulmonary syndrome	Contraindicated			

### Download English Version:

# https://daneshyari.com/en/article/3461054

Download Persian Version:

https://daneshyari.com/article/3461054

<u>Daneshyari.com</u>